sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Środki przeciwnowotworowe - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
sunitinib teva 12,5 mg kapsułki twarde
teva b.v. - sunitinibum - kapsułki twarde - 12,5 mg
sunitinib teva 25 mg kapsułki twarde
teva b.v. - sunitinibum - kapsułki twarde - 25 mg
sunitinib teva 37,5 mg kapsułki twarde
teva b.v. - sunitinibum - kapsułki twarde - 37,5 mg
sunitinib teva 50 mg kapsułki twarde
teva b.v. - sunitinibum - kapsułki twarde - 50 mg
sunitinib alvogen 12,5 mg kapsułki twarde
alvogen pharma trading europe eood - sunitinibum - kapsułki twarde - 12,5 mg
sunitinib alvogen 25 mg kapsułki twarde
alvogen pharma trading europe eood - sunitinibum - kapsułki twarde - 25 mg
sunitinib alvogen 37,5 mg kapsułki twarde
alvogen pharma trading europe eood - sunitinibum - kapsułki twarde - 37,5 mg
sunitinib alvogen 50 mg kapsułki twarde
alvogen pharma trading europe eood - sunitinibum - kapsułki twarde - 50 mg
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Środki przeciwnowotworowe - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.